Dasatinib is a potent second-generation tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. While primarily used as an antineoplastic agent for Philadelphia chromosome-positive leukemias, it is increasingly studied in longevity research as a senolytic due to its ability to selectively induce apoptosis in senescent cells.

Overview

Dasatinib is a second-generation tyrosine kinase inhibitor originally developed by Bristol-Myers Squibb and approved by the FDA for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It works by inhibiting multiple kinases including BCR-ABL, SRC family kinases, c-KIT, and PDGFR, providing broader target coverage than its predecessor imatinib.

In the longevity and anti-aging field, dasatinib has emerged as a leading senolytic compound—an agent that selectively eliminates senescent cells. The combination of dasatinib plus quercetin (D+Q) was identified by researchers at the Mayo Clinic as one of the first effective senolytic regimens. Senescent cells accumulate with age and secrete a pro-inflammatory senescence-associated secretory phenotype (SASP) that drives tissue dysfunction. Dasatinib targets senescent preadipocytes and other cell types by inhibiting the pro-survival tyrosine kinase networks they depend on.

Preclinical studies of D+Q have demonstrated improvements in physical function, reduced frailty, extended healthspan, and even increased lifespan in aged mice. Early human trials have shown reductions in senescent cell burden in patients with idiopathic pulmonary fibrosis and diabetic kidney disease. The senolytic protocol typically involves intermittent dosing (e.g., 3 consecutive days per month) rather than continuous administration, reflecting the "hit-and-run" nature of senolytic therapy.

Mechanism of Action

"

BCR-ABL Tyrosine Kinase Inhibition\n\nDasatinib is a potent second-generation oral multi-kinase inhibitor originally developed for chronic myelogenous leukemia (CML). It binds both the active and inactive conformations of the BCR-ABL fusion oncoprotein with 325-fold greater potency than imatinib, inhibiting its constitutive tyrosine kinase activity. This blocks Ras/MAPK, PI3K/Akt, and STAT5 downstream signaling cascades that drive leukemic cell proliferation and survival (PMID: 16397263).\n\n

Src Family Kinase Inhibition\n\nUnlike imatinib, dasatinib potently inhibits all Src family kinases (SFK) — Src, Lck, Fyn, Yes, and Lyn — with IC50 values in the low nanomolar range. SFK inhibition disrupts integrin signaling, focal adhesion turnover, and cytoskeletal remodeling, which are critical for cell migration, invasion, and bone marrow stromal interactions in hematologic malignancies (PMID: 17409472).\n\n

Senolytic Activity\n\nDasatinib has gained significant attention as a senolytic agent when combined with quercetin (D+Q). Senescent cells depend on pro-survival networks involving SFK, PI3K/Akt, p21, BCL-2/BCL-xL, and serpins. Dasatinib disrupts these anti-apoptotic pathways preferentially in senescent human preadipocytes and endothelial cells, inducing apoptosis while sparing quiescent and proliferating cells. The D+Q combination targets complementary senescent cell types (PMID: 25754370).\n\n

Additional Kinase Targets\n\nDasatinib inhibits c-KIT, PDGFR-alpha/beta, and ephrin receptor kinases at clinically relevant concentrations. Its broad kinase profile also affects immune cell function: Lck inhibition suppresses T-cell receptor signaling, while Fyn inhibition modulates NK cell activity, contributing to both therapeutic immunomodulation and off-target immunosuppressive effects."

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Dasatinib

Common Side Effects

• Myelosuppression: neutropenia, thrombocytopenia, anemia (very common at oncologic doses)
• Fluid retention: peripheral edema, pleural effusion (up to 35% of patients at standard doses)
• Gastrointestinal: diarrhea, nausea, vomiting, abdominal pain
• Headache, fatigue, musculoskeletal pain
• Skin rash, pruritus
• Hemorrhage (minor bleeding events)

Serious Adverse Effects

• Pleural and pericardial effusions: Can be severe and life-threatening; requires monitoring even at senolytic doses
• Pulmonary arterial hypertension (PAH): Rare but potentially irreversible; reported even after drug discontinuation
• Severe myelosuppression: May require dose reduction, interruption, or growth factor support
• QT prolongation: Risk of cardiac arrhythmias; avoid in patients with long QT syndrome
• Severe hemorrhage: Including CNS and GI bleeding (more common with concurrent anticoagulation)
• Hepatotoxicity: Elevated transaminases; rare severe liver injury
• Tumor lysis syndrome: In hematologic malignancies

Contraindications

• Known hypersensitivity to dasatinib
• Severe hepatic impairment (may increase drug exposure significantly)
• Congenital long QT syndrome or concurrent use of strong QT-prolonging medications
• Uncontrolled or significant cardiovascular disease
• Pregnancy (Category D) — teratogenic; effective contraception required
• Breastfeeding (drug excreted in milk)

Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir): Significantly increase dasatinib levels
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort): Dramatically reduce efficacy
• Proton pump inhibitors, H2 blockers, antacids: Reduce absorption (dasatinib requires acidic pH); avoid PPIs, separate antacids by 2 hours
• Anticoagulants/Antiplatelets: Increased bleeding risk
• QT-prolonging drugs: Additive cardiac risk
• Quercetin (senolytic combination): May modestly affect CYP3A4 metabolism; interaction appears clinically manageable at senolytic doses

Population-Specific Considerations

• Senolytic use: Intermittent dosing (e.g., 3 days per month) reduces but does not eliminate risks — pleural effusion and PAH monitoring still essential
• Elderly: Increased risk of fluid retention and myelosuppression; baseline echocardiogram recommended
• Hepatic impairment: Dose reduction required; avoid in severe impairment
• Renal impairment: No dose adjustment needed but monitor closely
• Reproductive age: Teratogenic — reliable contraception mandatory for both sexes

Pharmacokinetic Profile